Peptide directoryWhole body

Pancreastatin

A chromogranin A fragment that pushes glucose up and insulin’s effect down.

Where it comes from

Made in
Islet cells, chromaffin cells and neuroendocrine tumours, cut from chromogranin A
Sent out by
With insulin and catecholamines
Acts on
  • Liver (glycogen breakdown)
  • Fat cells (less glucose uptake)
  • Beta cells (less insulin)

What it does

  • Raises blood glucose and blunts insulin’s effect 1
  • Mice without chromogranin A are more insulin-sensitive, and giving pancreastatin undoes that
  • A common variant (Gly297Ser) makes the more potent peptide and carries a 1.3 to 1.6-fold risk of diabetes, hypertension and coronary disease 2

In medicine

  • A research marker in neuroendocrine tumours: in one series of 92 patients it was raised in 64 percent, against 43 percent for chromogranin A itself 3
  • No approved medicine copies it or blocks it, so the interest in it is as a measurement

Beyond the body’s own use

  • PSTi8, a peptide that blocks pancreastatin, lowered insulin resistance and fat accumulation in obese and diabetic mice; it has not been given to a person 4
  • Nothing containing pancreastatin is approved and it is not taken outside medicine. The open question is whether blocking it helps human type 2 diabetes as it helps the mouse 4

Sources

  1. Tatemoto et al., Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion, Nature 1986
  2. Allu et al., Functional Gly297Ser variant of pancreastatin as a cardiometabolic risk factor, Diabetes 2022
  3. Rustagi et al., Serum pancreastatin as a predictive neuroendocrine tumour marker, Journal of Surgical Oncology 2013
  4. Gupta et al., Pancreastatin inhibitor PSTi8 in hyperinsulinaemia-induced obesity, European Journal of Pharmacology 2019

This card describes what a medicine is for and what the evidence says; it recommends nothing. Talk to your clinician about anything you read here.